This year
liraglutide went generic while everybody was watching wegovy
On February 24, 2026, the FDA approved Biocon's gSaxenda — generic liraglutide injection for chronic weight management — with almost no coverage in the mainstream health press. [Biocon's February 2026 FDA approval](https://www.pearceip.law/2026/02/24/biocons-generic-liraglutide-injection-fda-approved/) was the second generic GLP-1 weight-loss approval in the U.S., following Teva's [first-to-market generic Saxenda launch in August 2025](https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2025/Teva-Announces-FDA-Approval-and-Launch-of-Generic-Saxenda-liraglutide-injection--First-Generic-GLP-1-Indicated-for-Weight-Loss/default.aspx). Both events arrived in the shadow of a louder story: oral Wegovy launched January 5, 2026, surpassed 2 million prescriptions in its first four months, and dominated every GLP-1 conversation that followed. By September 2026, generic liraglutide is available from multiple manufacturers at U.S. pharmacies. A GoodRx coupon puts a month's supply at roughly $226 — against $1,267 or more for brand-name Saxenda. That price gap is genuinely new. The molecule is not. Liraglutide was the weight-loss GLP-1 before Wegovy existed, and the original version of the drug — Victoza, for type 2 diabetes — launched in the U.S. in 2010. The oral-Wegovy era made it look old. The generic era just made it cheap. What that means for the thousands of patients and prescribers re-evaluating their options this fall is the question the conversation is not having.
The actual biology
liraglutide was the glp-1 receptor agonist before the daily shot became a weekly shot
Liraglutide is a GLP-1 receptor agonist — a synthetic analog of glucagon-like peptide 1, the incretin hormone the gut releases in response to food. GLP-1 receptor activation does several things that matter for weight management: it suppresses appetite through central and peripheral mechanisms, slows gastric emptying in a dose-dependent context, and drives glucose-dependent insulin secretion. Liraglutide is given as a once-daily subcutaneous injection, titrated over several weeks to the maintenance level used in the SCALE weight-management trials. Its half-life is roughly 13 hours — long enough for once-daily use, but far shorter than semaglutide's approximately 165–184 hour half-life, which enables weekly dosing. That pharmacokinetic gap is the biology behind the convenience story: liraglutide requires daily injection, the newer drugs do not. [PubMed indexes over 5,500 publications on liraglutide](https://pubmed.ncbi.nlm.nih.gov/?term=liraglutide), across cardiovascular, metabolic, renal, and weight-management contexts — a research footprint built over 15 years of post-approval study. The mechanism is well understood. The comparative question is whether the daily injection requirement and modestly smaller effect size still make clinical sense in the semaglutide era, particularly for patients priced out of the newer drugs.
What the market says
saxenda was the weight-loss glp-1 before wegovy and now it is the legacy option
Before Wegovy launched in 2021 and semaglutide achieved dominant brand recognition, Saxenda was the weight-loss GLP-1. Prescribers used it, clinics promoted it, and the $1,300 monthly price tag was standard for the category. The narrative shifted entirely after 2021. Today, liraglutide's most common online use case is comparison — patients asking whether to start on it versus a more expensive option, whether to stay on it versus switching, or whether the new generic version is actually the same drug. The answer to the last question is unambiguous: the FDA approval process for generics requires demonstrating bioequivalence to the brand, meaning the generic delivers the same amount of active drug in the same way. The comparison questions are harder. In the SUSTAIN 10 head-to-head trial, weekly semaglutide produced greater weight loss and metabolic benefit than daily liraglutide in a type 2 diabetes population. [SUSTAIN 10 trial data is indexed on PubMed](https://pubmed.ncbi.nlm.nih.gov/31517681/). The weight-management literature shows a similar pattern. What is not straightforward is whether the price gap now justifies a clinical trade-off that would have been a non-conversation two years ago.
What the data shows
the trials are old, the evidence is solid, and the head-to-head results are honest
Liraglutide's clinical evidence base is among the most established of any weight-management peptide. The SCALE trial program established the Saxenda weight-management indication in large randomized controlled trials, showing roughly 8–9% body weight reduction versus approximately 2–3% with placebo at 56 weeks. [ClinicalTrials.gov documents the SCALE obesity program](https://clinicaltrials.gov/search?term=liraglutide+SCALE+obesity). The LEADER trial established a cardiovascular benefit in a high-risk type 2 diabetes population — a 13% reduction in the primary composite cardiovascular endpoint versus placebo. Liraglutide also carries a separate FDA-approved indication for type 2 diabetes (Victoza) with LEADER-backed cardiovascular outcome data. The [current DailyMed label for Saxenda](https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=liraglutide) holds the full approved indication, clinical study history, and labeled risks. The key number the comparative literature supplies: in SUSTAIN 10, the semaglutide arm lost approximately 3.8 percentage points more body weight than the liraglutide arm. For some patients that gap matters clinically; for others, a cost differential of more than $1,000 a month matters more. Both are real variables.
Approved — PeptideFactCheck stance
the evidence is solid — what changed is the cost structure around it
Liraglutide holds PeptideFactCheck's Approved evidence tier — not because it is the most effective GLP-1, but because an approved label backed by a rigorous clinical program is a genuine thing, and liraglutide's is backed by more published human evidence than almost any compound covered on this site. [The FDA DailyMed record for liraglutide](https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=saxenda) holds the approved indication, contraindications, and full trial history. The Teva and Biocon generic approvals mean that FDA has reviewed bioequivalence — so the same FDA-reviewed drug is now available at licensed pharmacies at a fraction of brand-name pricing. What the generic approvals do not change: the comparative efficacy data. Semaglutide and tirzepatide produce larger weight loss in trials. That has been true since before the generics existed and will stay true after the generic market matures. The honest version of the liraglutide story in September 2026: a 15-year safety dataset, two approved indications, a cardiovascular outcomes trial, and a bioequivalent generic at about $226 a month. The Approved tier is not a ranking; it describes a level of evidence certainty. That certainty exists for liraglutide for specific labeled uses. For everything the internet adds on top of that, the source trail still has to come first.
Editorial boundary
What this page will not do
It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.